Nureca Limited

BSE: NURECA543264ISIN INE0DSF01015

Healthcare
Medical Equipment & Supplies

Share price

₹301.65-6.00 (-1.95%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹375.00
52W low: ₹200.10
Off 52W high: -19.56%
1M return: -12.79%
3M return: -12.06%
6M return: +6.31%
1Y return: +17.10%
20D avg volume: 645
50 DMA: ₹328.14
200 DMA: ₹286.42

Key ratios Consolidated

Market cap: ₹287.83 Cr
Current price: ₹301.65
52W high / low: ₹375.00 / ₹200.10
Face value: ₹10.00
P/E: 60.46
P/B: 1.53
EPS (TTM): ₹4.99
Book value / share: ₹196.90
ROE: —
ROCE: 3.40%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-0.74 Cr
Interest cover: 4.89
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 124.6 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	58.53	40.34	35.41	39.64	37.74	34.18	31.74	26.46	31.19	20.27	16.97	22.37
	1.35	1.82	1.02	2.19	2.32	2.57	1.99	1.48	3.17	5.79	1.26	5.90
	59.88	42.16	36.42	41.83	40.06	36.75	33.73	27.94	34.36	26.06	15.71	28.27
	54.36	37.73	41.93	37.17	35.46	35.52	31.68	31.19	34.44	23.44	22.18	27.33
	6.14	4.96	8.16	10.34	5.76	4.08	3.85	4.00	2.40	1.04	1.05	4.40
	52.17	13.52	12.38	24.86	17.02	18.93	25.16	14.31	12.92	11.28	7.50	4.95
	4.11	4.43	4.10	4.32	4.17	4.45	4.27	3.84	3.63	3.56	3.07	3.28
	0.26	0.20	0.30	0.28	0.46	0.25	0.62	0.17	0.27	0.15	0.18	0.11
	0.81	0.61	0.45	0.50	0.54	0.53	0.52	0.54	0.62	0.66	0.60	0.59
	10.45	7.80	15.64	6.83	6.49	8.11	7.30	10.10	9.64	6.84	7.16	7.47
	5.52	4.43	-5.51	4.66	4.59	1.23	2.05	-3.25	-0.07	2.62	-6.47	0.94
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	5.52	4.43	-5.51	4.66	4.59	1.23	2.05	-3.25	-0.07	2.62	-6.47	0.94
	1.47	1.36	0.58	0.93	0.97	0.42	-0.42	0.45	0.41	0.96	2.33	0.78
	4.05	3.07	-6.09	3.73	3.63	0.81	2.47	-2.80	-0.48	1.66	-4.15	0.17
	4.25	3.21	-6.45	3.91	3.63	0.81	2.47	-2.80	-0.48	1.66	-4.15	0.16
Key metrics
	6.59	5.24	-4.76	5.44	5.59	2.01	3.19	-2.54	0.82	3.43	-5.69	1.64
	11.30%	13.00%	-13.40%	13.70%	14.80%	5.90%	10.10%	-9.60%	2.60%	16.90%	-33.50%	7.30%
	6.90%	7.60%	-17.20%	9.40%	9.60%	2.40%	7.80%	-10.60%	-1.50%	8.20%	-24.50%	0.80%
	3.00%	—	-2.90%	—	2.50%	—	1.40%	—	—	—	—	—
	55.10%	18.00%	11.60%	49.80%	21.00%	68.60%	87.00%	18.30%	—	—	—	—
	11.60%	279.00%	-346.60%	233.20%	856.20%	-51.20%	159.50%	-1,747.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	173.92	146.96	109.66	91.93	111.32	255.55
	6.38	8.10	12.44	10.51	7.11	7.70
	180.29	155.06	122.10	102.44	118.43	263.24
	171.19	150.08	120.75	104.99	129.17	202.26
	29.60	28.35	11.29	9.76	3.52	—
	102.93	73.19	63.68	46.47	41.24	159.55
	16.96	17.04	15.31	12.20	16.06	9.91
	1.04	1.28	1.21	0.49	0.45	0.74
	2.37	2.02	2.34	2.36	2.39	1.48
	40.72	37.07	33.88	29.32	—	—
	9.10	4.98	1.34	-2.54	-10.74	60.98
	0.00	0.00	0.00	0.00	0.00	0.00
	9.10	4.98	1.34	-2.54	-10.74	60.98
	4.34	2.90	0.50	0.75	2.49	16.02
	4.76	2.08	0.85	-1.79	-8.25	44.96
	4.92	2.11	0.85	-1.79	-8.25	44.96
Key metrics
	12.51	8.28	4.89	0.31	-7.90	63.20
	7.19%	5.60%	4.50%	0.30%	-7.10%	24.70%
	2.74%	1.40%	0.80%	-1.90%	-7.40%	17.60%
	—	3.40%	1.30%	—	—	—
	33.66%	34.00%	19.30%	-17.40%	-56.40%	—
	15.82%	144.70%	147.50%	78.30%	-118.30%	—
	—	-3.53	-23.40	—	—	—
	—	1.59	-22.45	—	—	—
	—	0.00	0.01	—	—	—
	—	-0.74	-0.87	—	—	—
	—	124.6	122.2	—	—	—
Balance sheet
	—	196.16	209.98	—	—	—
	—	114.67	189.95	—	—	—
	—	1.46	3.24	—	—	—
	—	7.75	3.32	—	—	—
	—	47.51	39.92	—	—	—
	—	15.70	16.47	—	—	—
	—	10.67	4.81	—	—	—
	—	5.08	6.56	—	—	—
	—	13.78	12.40	—	—	—
	—	0.72	2.37	—	—	—
	—	0.50	1.32	—	—	—
	—	0.22	1.05	—	—	—
	—	180.76	194.28	—	—	—
Cash flow
	—	3.30	-19.08	—	—	—
	—	14.49	8.44	—	—	—
	—	-19.56	-0.17	—	—	—
	—	6.83	4.32	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	58.60	40.40	35.41	39.64	37.84	34.32	31.75	27.21	32.37	23.31	19.56	22.37
	1.42	1.92	1.06	2.29	2.38	2.59	2.00	1.52	3.21	5.82	1.25	5.92
	60.02	42.31	36.47	41.92	40.22	36.92	33.75	28.73	35.58	29.13	18.31	28.30
	55.03	38.70	42.62	37.88	36.12	36.08	32.25	32.57	35.85	26.97	25.06	27.46
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	60.72	20.37	23.05	38.27	24.92	25.39	30.88	20.90	17.88	16.83	12.82	10.45
	3.67	4.03	3.66	3.90	3.79	4.08	3.98	3.60	3.39	3.38	2.91	3.10
	0.22	0.18	0.24	0.18	0.41	0.20	0.59	0.14	0.25	0.13	0.17	0.10
	0.76	0.57	0.43	0.46	0.48	0.48	0.47	0.49	0.57	0.61	0.56	0.56
	9.10	6.80	14.61	5.23	5.56	6.96	6.51	9.09	8.68	6.05	6.25	6.63
	4.99	3.62	-6.15	4.05	4.11	0.83	1.50	-3.85	-0.27	2.16	-6.74	0.83
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	4.99	3.62	-6.15	4.05	4.11	0.83	1.50	-3.85	-0.27	2.16	-6.74	0.83
	1.36	1.19	0.47	0.82	0.97	0.28	-0.57	0.56	0.38	0.97	2.33	0.75
	3.62	2.43	-6.62	3.23	3.14	0.55	2.07	-3.29	-0.65	1.20	-4.41	0.08
	3.80	2.55	-6.95	3.39	3.14	0.55	2.07	-3.29	-0.65	1.19	-4.41	0.08
Key metrics
	5.97	4.37	-5.48	4.69	5.00	1.51	2.56	-3.22	0.55	2.90	-6.01	1.49
	10.20%	10.80%	-15.50%	11.80%	13.20%	4.40%	8.10%	-11.80%	1.70%	12.40%	-30.70%	6.70%
	6.20%	6.00%	-18.70%	8.10%	8.30%	1.60%	6.50%	-12.10%	-2.00%	5.10%	-22.50%	0.40%
	2.80%	—	-3.30%	—	2.30%	—	1.10%	—	—	—	—	—
	54.90%	17.70%	11.50%	45.70%	16.90%	47.20%	62.30%	21.60%	—	—	—	—
	15.30%	341.80%	-419.80%	198.20%	583.10%	-54.20%	146.90%	-4,212.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	174.05	147.21	114.64	94.52	111.90	255.55
	6.69	8.32	12.54	10.56	7.17	7.72
	180.72	155.53	127.18	105.08	119.06	263.27
	174.23	152.69	127.64	108.35	130.02	201.94
	0.00	0.00	0.00	—	—	—
	142.41	111.62	86.49	63.19	47.08	159.53
	15.26	15.43	14.36	11.57	15.51	9.83
	0.82	1.03	1.11	0.46	0.43	0.73
	2.22	1.85	2.15	2.24	2.30	1.43
	35.74	32.36	30.33	26.74	33.98	57.33
	6.51	2.84	-0.46	-3.27	-10.96	61.33
	0.00	0.00	0.00	—	—	—
	6.51	2.84	-0.46	-3.27	-10.96	61.33
	3.84	2.54	0.21	0.83	2.54	16.02
	2.66	0.30	-0.67	-2.44	-8.42	45.31
	2.79	0.30	-0.67	-2.44	-8.42	45.31
Key metrics
	9.55	5.72	2.80	-0.57	-8.23	63.49
	5.49%	3.90%	2.40%	-0.60%	-7.40%	24.80%
	1.53%	0.20%	-0.60%	-2.60%	-7.50%	17.70%
	—	2.20%	0.30%	—	—	—
	32.74%	28.40%	21.30%	-15.50%	-56.20%	—
	7.69%	144.80%	72.50%	71.00%	-118.60%	—
	—	-5.05	-22.54	—	—	—
	—	1.07	27.69	—	—	—
	—	0.00	0.01	—	—	—
	—	-0.73	-1.66	—	—	—
	—	120.9	109.6	—	—	—
Balance sheet
	—	193.54	206.16	—	—	—
	—	110.47	184.38	—	—	—
	—	1.40	3.19	—	—	—
	—	9.78	4.53	—	—	—
	—	45.41	35.55	—	—	—
	—	11.57	13.49	—	—	—
	—	9.39	3.63	—	—	—
	—	6.42	5.66	—	—	—
	—	14.80	10.44	—	—	—
	—	0.67	1.53	—	—	—
	—	0.45	0.48	—	—	—
	—	0.22	1.05	—	—	—
	—	177.16	192.48	—	—	—
Cash flow
	—	0.32	-18.55	—	—	—
	—	16.50	8.56	—	—	—
	—	-18.61	-0.79	—	—	—
	—	5.37	3.99	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.57%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +32.74%
Profit YoY (TTM): +7.69%

Consolidated

Sales CAGR 3Y: +9.70%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +33.66%
Profit YoY (TTM): +15.82%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 70.68%

Quarter	September 2026	June 2026
Promoter %	70.68%	68.09%

Holder	Type	Holding	Previous	Change
Saurabh Goyal	Promoter	70.08%	34.35%	+35.73%
Smita Goyal	Promoter Group	0.60%	0.00%	+0.60%
Payal Goyal	Promoter Group	0.00%	21.59%	-21.59%
Aryan Goyal	Promoter Group	0.00%	12.15%	-12.15%
Nectar Biopharma Private Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Poly Medicure Ltd	16,093	1,587.65	51.43	13.20%	+18.31% TTM	-12.49% TTM	-18.70%
MOLBIO DIAGNOSTICS LIMITED	15,901	1,379.80	—	—	—	—	—
Sahajanand Medical Technologies Limited	4,939	485.85	—	—	—	—	—
FISCHER MEDICAL VENTURES LIMITED	1,655	25.29	59.29	12.70%	+195.94% TTM	+371.52% TTM	-73.00%
Tarsons Products Limited	1,651	310.35	148.83	4.80%	+10.63% TTM	-59.68% TTM	+7.85%
Laxmi Dental Limited	1,036	188.30	31.98	11.50%	+13.07% TTM	+24.85% TTM	-40.71%
Hemant Surgical Industries Limited	884	608.10	—	19.50%	—	—	+109.69%
Fabtech Technologies Limited	591	133.05	16.61	11.60%	—	—	-44.16%
Prevest Denpro Limited	480	400.00	—	21.90%	—	—	-23.80%
Nureca Limited	288	301.65	60.46	3.40%	+33.66% TTM	+15.82% TTM	+17.10%
EARKART LIMITED S	161	117.00	32.59	12.10%	—	—	-48.46%
CHOKSI ASIA LIMITED S	120	210.00	23.08	18.40%	+21.40% TTM	+132.74% TTM	+97.28%
Shree Pacetronix Ltd	63	169.15	19.60	25.00%	+22.63% TTM	+208.57% TTM	-38.65%
Amkay Products Limited S	46	53.50	20.04	13.40%	—	—	+13.88%
KMS Medisurgi Limited S	44	132.80	177.07	4.80%	—	—	—
Royal Sense Limited	36	67.70	—	26.10%	—	—	-70.69%
GKB Ophthalmics Ltd.	31	62.00	5.67	9.60%	+29.95% TTM	+170.50% TTM	-9.48%
Centenial Surgical Suture Ltd. S	26	71.96	-17.99	2.60%	+6.70% TTM	+26.29% TTM	-33.37%
Transpact Enterprises Limited S	4	100.70	—	14.50%	—	—	-57.35%

Some figures use IPO-document inputs. Growth periods are shown per value; FY means annual.

Filings & corporate actions

Recent announcements

Intimation about Credit Rating3 Nov 2026 · Company Update / Credit Rating
Copy of Newspaper Publication22 Oct 2026 · Company Update / Newspaper Publication
Nureca records highest quarterly revenue in last 20 quarters ;Q2 revenue rises 55% to Rs. 58.53 crore .21 Oct 2026 · Company Update / Press Release / Media Release
Un-audited Financial results for the quarter and half year ended 30th September,202621 Oct 2026 · Board Meeting / Outcome of Board Meeting
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.17 Oct 2026 · Company Update / General
Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants ) Regulations ,2018.15 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Nureca Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2026 ,inter alia, to consider and approve inter-alia, the un-audited Financial ....14 Oct 2026 · Board Meeting / Board Meeting
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")1 Oct 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")30 Sep 2026 · Company Update / General
Closure of Trading Window29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")29 Sep 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")28 Sep 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")26 Sep 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading ) Regulations ,2015 ("PIT Regulations")25 Sep 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations).10 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Saurabh Goyal10 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Smita Goyal10 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations)9 Sep 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading ) Regulations ,2015 ("PIT Regulations ")29 Aug 2026 · Company Update / General
Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading )Regulations ,2015 (PIT Regulations )11 Aug 2026 · Company Update / General
Additional details required for Corporate Announcement under Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.10 Aug 2026 · Company Update / General
Pendency of Litigation(s)/disput(s) or the outcome impacting the Company.7 Aug 2026 · Company Update / General
Scrutinizer Report and Voting Results for the 10th Annual General Meeting28 Jul 2026 · AGM/EGM / AGM
Outcome and Proceedings of the 10th Annual General Meeting.28 Jul 2026 · AGM/EGM / AGM
Copy of Newspaper publication22 Jul 2026 · Company Update / Newspaper Publication
Unaudited Financial results for the quarter ended June 30, 202621 Jul 2026 · Result / Financial Results
Investor Presentation for Q1 & FY''2721 Jul 2026 · Company Update / Investor Presentation
Un-audited Financial Results for the quarter ended June 30, 2026.21 Jul 2026 · Board Meeting / Outcome of Board Meeting
Compliance certificate under Reg 74(5) of SEBI(DP) Regulations,201815 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Nureca Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 ,inter alia, to consider and approve Nureca Limited has informed the exchange ....14 Jul 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....9 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Saurabh Goyal8 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Resubmission of a More Legible Copy of the Notice of 10th Annual General Meeting ('AGM') and Annual Report 2025-26 submitted on 03 July 2026.8 Jul 2026 · Others / Reg. 34 (1) Annual Report
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Saurabh Goyal6 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Payal Goyal6 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aryan Goyal6 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Nureca Limited has informed the exchange regarding newspaper publication.4 Jul 2026 · Company Update / Newspaper Publication
Nureca Limited has informed the exchange regarding Notice of 10th AGM of the company along with its Annual Report for the FY25-26.3 Jul 2026 · AGM/EGM / AGM
Nureca Limited has informed the exchange regarding Annual Report for the FY 25-26.3 Jul 2026 · Others / Reg. 34 (1) Annual Report
Nureca Limited has informed the exchange regarding disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT Regulations")3 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Buy Back of Shares	12 Dec 2025	12 Dec 2025	—

Board meetings

21 Oct 2026 Board Meeting - Financial Results
21 Jul 2026 Board Meeting - Financial Results